TNFRSF8 and Hodgkins lymphoma: The first phase I clinical study of this ADC was conducted in 45 relapsed or refractory patients with CD30-positive hematologic malignancies, including Hodgkin’s lymphoma (HL), anaplastic large-cell lymphoma (ALCL), and angioimmunoblastic T-cell lymphoma [100].